Cambrex
CBM | US
Overview
Corporate Details
- ISIN(s):
- US1320111073
- LEI:
- 4Q9DLX2VIFGJMOYJ4Y35
- Country:
- United States of America
- Address:
- N/A
- Website:
- https://www.cambrex.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Cambrex filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cambrex
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cambrex via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Offers a Xenon gas drug-device for non-invasive, radiation-free MRI of lung function.
United States of America
POLX
United States of America
POLX
South Korea
041910
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
Switzerland
PPGN
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
United States of America
PYPD
Develops hydrogel nasal sprays for pathogen protection and intranasal drug delivery.
United States of America
PLRZ
United States of America
PLRZ
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom
POLB
United Kingdom
POLB
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
United States of America
PRAX
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
United States of America
PGEN
South Korea
335810
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
United States of America
PRLD